Inovio Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, INO, Inovio Pharmaceuticals Inc, priceseries

Inovio Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.06
Close
3.16
High
3.22
Low
3.04
Previous Close
3.11
Daily Price Gain
0.05
YTD High
5.27
YTD High Date
Jan 4, 2022
YTD Low
2.76
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.04
YTD Gain
-39.23%
52 Week High
10.82
52 Week High Date
Mar 16, 2021
52 Week Low
2.76
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-5.75
52 Week Gain
-64.53%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
6.60
May 30. 2017
7.46
12 Trading Days
13.01%
Link
LONG
Jan 22. 2018
4.64
Jan 29. 2018
4.88
5 Trading Days
5.14%
Link
LONG
Aug 21. 2018
4.54
Sep 13. 2018
5.31
16 Trading Days
16.86%
Link
LONG
Sep 25. 2018
5.05
Oct 5. 2018
5.42
8 Trading Days
7.31%
Link
LONG
Jan 3. 2019
4.28
Jan 14. 2019
4.61
7 Trading Days
7.63%
Link
LONG
Apr 2. 2019
3.70
Apr 16. 2019
3.96
10 Trading Days
7.05%
Link
LONG
Sep 9. 2019
2.19
Sep 19. 2019
2.47
8 Trading Days
12.77%
Link
LONG
Dec 18. 2019
2.63
Jan 2. 2020
3.18
9 Trading Days
20.95%
Link
LONG
Feb 13. 2020
3.86
Feb 19. 2020
4.08
3 Trading Days
5.57%
Link
LONG
Mar 3. 2020
7.45
Mar 10. 2020
8.33
5 Trading Days
11.78%
Link
LONG
Apr 16. 2020
7.89
Apr 30. 2020
12.14
10 Trading Days
53.81%
Link
LONG
May 11. 2020
11.90
May 27. 2020
13.10
11 Trading Days
10.11%
Link
LONG
Jun 12. 2020
13.02
Jul 1. 2020
22.89
13 Trading Days
75.77%
Link
LONG
Jan 25. 2021
9.72
Feb 4. 2021
12.21
8 Trading Days
25.63%
Link
LONG
Jun 4. 2021
7.94
Jun 15. 2021
8.67
7 Trading Days
9.22%
Link
Company Information
Stock Symbol
INO
Exchange
NasdaqGS
Company URL
http://www.inovio.com
Company Phone
858 597-6006
CEO
J. Joseph Kim
Headquarters
California
Business Address
10480 WATERIDGE CIRCLE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001055726
About

Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company's portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Description

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading